Dualitybio：Completed IPO coaching and proposes listing on the STAR Market.
On June 10, DualityBio announced that the coaching for its RMB-denominated shares to be listed on the STAR Market has passed the acceptance inspection by the Shanghai Regulatory Bureau.
Founded in 2019, DualityBio focuses on the research and development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, autoimmune diseases, and other conditions. On April 15, 2025, DualityBio was officially listed on the Hong Kong Stock Exchange. In November 2025, DualityBio filed its IPO pre-IPO coaching filing with the Shanghai Regulatory Bureau. In April 2026, DualityBio announced that its board of directors had approved its STAR Market IPO.
Currently, DualityBio has four innovative ADC technology platforms, including: Duality Immune Toxin Antibody Conjugate (DITAC), Duality Innovative Bispecific Antibody Conjugate (DIBAC), Duality Immune-modulating Antibody Conjugate (DIMAC), and Duality Novel Payload Conjugate Platform (DUPAC). Based on these platforms, DualityBio has developed multiple ADC drug candidates, among which Patritumab Deruxtecan has already been submitted for marketing approval in China. In addition, core products such as DB-1310 and DB-1311 have also initiated multiple clinical trials.
Buy DB-1310/DB-1311 from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
